FindTrial
Sign In

Test with patients seeking to demonstrate the efficacy of Hycos MG500 I in assisting skin regeneration

Clinical study, single-blind, of the efficacy and safety of the product Hycos MG500 I

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-547cnx9
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-05-30
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Ulcer

Interventions

This study aims to demonstrate the efficacy and safety of the product Hycos Mg500 I, a cream solution intended for skin regeneration. The study was conducted with a single group in a single-blind, sin
G16.762.891

Sponsors

Nipo Serviços Médicos SS Ltda
Lead Sponsor
Instituto de Saúde e Bem Estar da Mulher
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: The participating patient has a wound, lesion, or bedsore. The injury requires dressings. Age between 18 and 90 years old. Any ethnicity, color/race, and skin phototype. Both genders. Patients are in the early stages of treatment

Exclusion criteria

Exclusion criteria: Pregnancy. Neonates. Sensitivity to the components of the medication

Design outcomes

Primary

MeasureTime frame
To prove the efficacy and safety of Hycos Mg500I in humans affected by chronic or acute wounds—

Secondary

MeasureTime frame
To demonstrate its use in protecting and hydrating irritated and dry skin caused by wound exudates, helping to restore the skin's natural pH and preventing skin lesions—

Countries

Brazil

Contacts

Public ContactFrederico Viana

TCI Laboratório Biotecnológico Ltda

frederico@tcilab.com.br+55 38 99886-3565

Outcome results

None listed

Source: REBEC (via WHO ICTRP)